Literature DB >> 21981352

Beneficial effect of acitretin in Chanarin-Dorfman syndrome.

S Israeli1, Y Pessach, O Sarig, I Goldberg, E Sprecher.   

Abstract

Chanarin-Dorfman syndrome (CDS) is an autosomal recessive metabolic disorder characterized by congenital ichthyosis and visceral complications due to accumulation of neutral lipids. CDS is caused by mutations in the ABHD5 (previously termed CGI-58) gene. In the present study, we assessed a young child presenting with ichthyosis and hepatomegaly, suggesting a diagnosis of CDS. We identified an intronic mutation, c.960 + 5G>A, which was found to result in skipping of exon 6. Abnormal results on liver function tests led us to treat the child with acitretin, which resulted in satisfactory clinical and laboratory responses. The present case illustrates the beneficial effect of acitretin treatment in CDS even in the presence of compromised liver function. © The Author(s). CED
© 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21981352     DOI: 10.1111/j.1365-2230.2011.04164.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  10 in total

Review 1.  CGI-58: Versatile Regulator of Intracellular Lipid Droplet Homeostasis.

Authors:  Liqing Yu; Yi Li; Alison Grisé; Huan Wang
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  Dorfman-Chanarin Syndrome: A Rare Cause of Metabolic Associated Fatty Liver Disease Related to Homozygosity of the Nonsense Mutation c.934C>T (p.R312*).

Authors:  Rita Quelhas da Costa; Francisco Laranjeira; Isaura Duarte Ribeiro; António Filipe Santos; Filipe Nery
Journal:  GE Port J Gastroenterol       Date:  2021-07-07

Review 3.  Inborn errors of cytoplasmic triglyceride metabolism.

Authors:  Jiang Wei Wu; Hao Yang; Shu Pei Wang; Krishnakant G Soni; Catherine Brunel-Guitton; Grant A Mitchell
Journal:  J Inherit Metab Dis       Date:  2014-10-10       Impact factor: 4.982

4.  Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  A Manta; S Spendiff; H Lochmüller; R Thompson
Journal:  J Neuromuscul Dis       Date:  2021

5.  Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents.

Authors:  Andrea L Zaenglein; Moise L Levy; Nicole S Stefanko; Latanya T Benjamin; Anna L Bruckner; Keith Choate; Brittany G Craiglow; John J DiGiovanna; Lawrence F Eichenfield; Peter Elias; Philip Fleckman; Leslie P Lawley; Richard A Lewis; Anne W Lucky; Erin F Mathes; Leonard M Milstone; Amy S Paller; Sonali S Patel; Dawn H Siegel; Joyce Teng; Sherry A Tanumihardjo; Lauren Thaxton; Mary L Williams
Journal:  Pediatr Dermatol       Date:  2020-11-10       Impact factor: 1.588

6.  Recurrent N209* ABHD5 mutation in two unreported families with Chanarin Dorfman Syndrome.

Authors:  Daniela Tavian; Murat Durdu; Corrado Angelini; Enza Torre; Sara Missaglia
Journal:  Eur J Transl Myol       Date:  2021-05-12

7.  Case Report: Chanarin-Dorfman Syndrome: A Novel Homozygous Mutation in ABHD5 Gene in a Chinese Case and Genotype-Phenotype Correlation Analysis.

Authors:  Bo Liang; He Huang; Jiaxiang Zhang; Gang Chen; Xiangsheng Kong; Mengting Zhu; Peiguang Wang; Lili Tang
Journal:  Front Genet       Date:  2022-03-28       Impact factor: 4.599

8.  Chanarin-Dorfman syndrome treatment with acitretin.

Authors:  Reem AlNeyadi; Shaden Abdelhadi; Zbigniew Ruszczak
Journal:  JAAD Case Rep       Date:  2022-03-31

9.  Chanarin-Dorfman Syndrome with Absent Jordan's Anomaly.

Authors:  Sandeep Arora; Shuvendu Roy; Divya Arora; Chetan Patil; Arun Kumar Jain
Journal:  Indian J Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.494

10.  A novel mutation of ABHD5 gene in a Chanarin Dorfman patient with unusual dermatological findings.

Authors:  Ali Haydar Eskiocak; Sara Missaglia; Laura Moro; Murat Durdu; Daniela Tavian
Journal:  Lipids Health Dis       Date:  2019-12-28       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.